SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is trending following unconfirmed market buzz regarding potential M&A activity, leading to heightened trading volume and retail investor speculation. The community is actively debating the company's valuation, the credibility of buyout rumors, and the underlying strength of its commercial HAE franchise.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE has emerged as a trending meme coin, triggering polarized community debate between retail investors chasing rapid momentum and skeptics warning of a potential pump-and-dump scheme. While some traders tout its chart structure and low entry point as evidence of growth potential, critics highlight concentrated ownership among top holders and the lack of fundamental utility as major red flags.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

The Fundrise Innovation Fund (VCX) is seeing intense volatility and massive retail interest following its recent market debut, with the community closely tracking its exposure to high-profile private AI and tech companies like Anthropic, SpaceX, and OpenAI. Traders are actively debating the sustainability of the stock's significant premium to its Net Asset Value, while many early investors are discussing the implications of the 6-month lock-up period on the tradable float.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide (WRD) is trending following multiple operational updates, including the rollout of fully driverless commercial robotaxi services in the Middle East through an Uber partnership and successful autonomous driving competitions in China. While investors are actively debating the company's valuation gap compared to sector peers and its long-term scaling strategy, sentiment is heavily influenced by institutional accumulation, including increased holdings by ARK Invest, contrasted against concerns regarding the CEO's limited communication and the stock's recent volatility.

Merlin, Inc. is an aerospace and defense technology company focused on developing autonomous flight solutions. The company is building an operating system of record for autonomous aviation, with its Merlin Pilot system enabling a wide range of aircraft and mission profiles. Its technology has been validated through hundreds of autonomous flights conducted at test facilities worldwide. The company is headquartered in Boston, MA.

Merlin Inc.

Marlin Business Services Corp.

The ticker $MRLN is trending as traders navigate confusion between the legacy Marlin Business Services entity and the recently listed Merlin, Inc., an AI-driven aviation firm that recently completed its SPAC merger. The community is actively debating the stock's valuation, potential defense sector catalysts, and the volatility inherent in this low-float setup, while also closely monitoring insider trading activity and institutional moves.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean (RIG) is currently capturing significant investor attention due to its pending merger with Valaris, which aims to create an offshore drilling powerhouse with improved pricing power and a massive contract backlog. The market is also heavily focused on RIG's operational turnaround and debt reduction efforts, while community discussions remain intensely volatile as traders weigh the impact of potential geopolitical instability in energy-rich regions against the stock's recent price momentum.

American Airlines Group, Inc. is a holding company, which engages in the operation of a network carrier through its principal wholly owned mainline operating subsidiary, American. The firm offers air transportation for passengers and cargo. It operates through the following geographical segments: Domestic, Latin America, Atlantic, and Pacific. The company was founded on December 9, 2013, and is headquartered in Fort Worth, TX.

American Airlines Group Inc

American Airlines is facing intense downward pressure as geopolitical volatility in the Middle East triggers massive flight disruptions and a sharp spike in jet fuel costs. The community is actively debating the stock's long-term viability, with many traders closely monitoring support levels while others speculate on the potential for a rapid recovery if the regional conflict de-escalates.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is surging as investors closely monitor earnings and guidance, with the community highly focused on potential new contract awards and the company's long-term growth in the space infrastructure sector. Shareholders are expressing strong bullish sentiment, betting on significant revenue expansion and future moon mission catalysts, while retail traders remain sharply divided over the stock's valuation and volatility.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending due to heightened volatility driven by concerns over institutional shelf offerings and sector-wide regulatory pressures, leading to intense debate among investors regarding whether the stock is an undervalued defensive play or caught in a sustained downtrend. Community discourse remains deeply divided between those accumulating shares for long-term dividends and skeptics who are actively trading puts, with both sides closely watching for upcoming Medicare Advantage rate announcements as a key catalyst.

Vanguard Malvern Funds - Vanguard Short-Term Inflation-Protected Securities Index Fund

Vanguard Short-Term Inflation-Protected Securities ETF

VTIP is currently trending as a focal point for traders looking to hedge against economic volatility, with community discussions heavily influenced by broader concerns over inflation, government spending, and the potential impacts of aggressive fiscal policies on the bond market. While some investors view the ETF as a defensive parking spot for capital, others are actively analyzing its RSI and MACD trends to identify entry points during the current climate of macroeconomic uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the sixteen ratings firms that are covering the firm, MarketBeat...

Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It?

BEAM shares jump 23% in six months as upbeat risto-cel data, pipeline expansion and new financing strengthen confidence in its gene-editing strategy.

ARK Investment Management LLC Increases Position in Beam Therapeutics Inc. $BEAM

ARK Investment Management LLC boosted its holdings in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 24.8% in the third quarter, according to its most recent Form 13F filing with the SEC. The...

What is HC Wainwright's Forecast for BEAM Q1 Earnings?

Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Stock analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Beam Therapeutics in a research note issued on Monday, March...

Vanguard Group Inc. Sells 455,440 Shares of Beam Therapeutics Inc. $BEAM

Vanguard Group Inc. reduced its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 4.7% in the third quarter, according to its most recent filing with the Securities...

Beam Therapeutics (NASDAQ:BEAM) Raised to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Beam Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday...

Beam Therapeutics (NASDAQ:BEAM) Trading Down 6.3% - Time to Sell?

Beam Therapeutics (NASDAQ:BEAM) Shares Down 6.3% - Here's Why...

BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y

Beam Therapeutics posts a narrower Q4 loss as revenues surge past estimates. It secures $500M financing, extending its cash runway into mid-2029. 

Beam Therapeutics (NASDAQ:BEAM) Price Target Raised to $26.00

Royal Bank Of Canada raised their price target on Beam Therapeutics from $22.00 to $26.00 and gave the stock a "sector perform" rating in a report on Wednesday...

Beam Therapeutics (NASDAQ:BEAM) Stock Price Expected to Rise, Wedbush Analyst Says

Wedbush boosted their target price on shares of Beam Therapeutics from $57.00 to $65.00 and gave the stock an "outperform" rating in a report on Wednesday...

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$1.02	--	--	N/A
Q4 '25	-$0.94	$2.33	348.45%	BEAT
Q3 '25	-$1.04	-$1.10	-5.99%	MISSED
Q2 '25	-$1.11	-$1.00	10.12%	BEAT
Q1 '25	-$1.18	-$1.24	-4.75%	MISSED

BEAM
Beam Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest BEAM News

BEAMBeam Therapeutics Inc